Drug therapy during pregnancy is unique in that therapy of one person, the pregnant woman, simultaneously exposes another, the fetus, to the same agent. 1 Maternal physiologic changes during pregnancy influence how drugs are distributed, metabolized, and excreted in the woman and thus placental transfer and fetal exposure. Levels of some agents are increased, with need for lower dose or less frequent dosing, or decreased, with need for higher dose or more frequent dosing. 2 Increased plasma volume, cardiac output, and total body water during pregnancy increase the volume of distribution for many drugs so that prepregnancy doses of chronically used drugs may not achieve the same effect. Accumulation of fat in pregnancy increases the volume of distribution for lipidsoluble drugs such as caffeine and sedatives and can prolong half-lives. Increased free fatty acids and steroids alter hepatic enzyme activity in the woman and may compete with drugs for albumin-binding sites, increasing the unbound or free drug fraction available for placental transfer. This can lead to unpredictability, with greater flux of peak and trough levels of agents such as phenytoin, salycilates, and phenobarbital. 3 Decreased serum albumin also increases free drug levels. Pulmonary changes in pregnancy increase alveolar uptake of volatile anesthetics.
2 Alterations in gastrointestinal (GI) function initially delay then prolong absorption of oral agents, increasing the time to peak drug levels. 2 Changes in skin and peripheral blood flow may increase absorption of topical and vaginal agents. The increased glomerular filtration rate during pregnancy may result in more rapid elimination of drugs. This increases the risk of subtherapeutic doses for drugs such as ampicillin, penicillin G, lithium, aminoglycosides, digoxin, and some antiepileptic agents. 4 Although this reduction in half-life is not clinically significant in most women, it can be in women with epilepsy and paroximal atrial tachycardia. 2, 4 Altered activity of some liver enzyme systems, especially CYP1A1, the enzyme system for elimination of over half of all drugs, and hepatic blood flow can lead to delayed or variable metabolism and degradation of some drugs and increases in others such as phenytoin. 4 Three patterns of placental drug transfer have been described. 5 Drugs with complete transfer rapidly equilibrate between mother and fetus. The limiting step in transfer of these agents is the rate of placental blood flow. Complete transfer is seen with magnesium sulfate, digoxin, cocaine, pentobarbital, and secobarbital. 5 In the second pattern, levels of drugs tend to be higher in fetus than in mother, as seen with lorazepam, diazepam, ampicillin, some penicillins, nicotine, and gentamicin. 5 In incomplete transfer, drug levels are higher in mother than in fetus (eg, lidocaine, propanolol, pancuronium, some sulfonamides in first and second trimester, and methadone). 5 Although most drugs cross the placenta by diffusion, some agents, such as amphetamines, cocaine, and nicotine, may be carried by nutrient transporters. 6 These agents often successfully compete with nutrients for these transporters, reducing nutrient transfer and fetal growth.
DRUG HANDLING IN THE NEONATE
Developmental alterations in GI, hepatic, skin, and renal physiology alter drug handling in the preterm and term neonates, making pharmacologic management of these infants especially challenging. Differences in GI function are an issue in the neonate and one of the reasons oral agents are used less frequently. Alternations in gastric pH may interfere with drug ionization (and absorption) or partially inactivate some drugs. For example, acidic drugs such as penicillin may be more readily absorbed in neonates whereas basic drugs such as theophylline and diazepam may have delayed absorption. Delayed gastric emptying and altered intestinal motility may delay absorption and reduce peak drug concentrations.
2 Antimicrobial drugs from birth may partially suppress colonization and shift dominant flora. Alterations in pancreatic enzymes and bile acid pools reduce absorption of lipid-soluble vitamins and drugs. Levels of the β-glucuronidase in the small intestine are elevated. 7 This enzyme may deconjugate substrates in bile acids, which are then reabsorbed into systemic circulation. This results in longer half-lives and prolonged activity of drugs such as chloramphenicol. 7 Skin immaturity increases permeability and systemic absorption of topical agents. The decreased muscle mass, especially in preterm infants, and blood flow in the first few days may delay uptake from intramuscular injections and lead to erratic absorption of intramuscular imedications, especially in ill infants. 2 Changes in body water and fat when combined with neonatal hepatic and renal function limitations may result in decreased peak volumes, need for larger loading doses, and delayed excretion of drugs such as theophylline, caffeine, phenobarbital, digoxin, and aminoglycisides. 7 Drugs in blood are either protein-bound or free. Newborns have lower levels of albumin and α-1 acid glycoprotein, the major drugbinding proteins in the blood. In addition, their albumin does not bind drugs as well, has fewer binding sites, and a decreased affinity for many substances. This is particularly evident in preterm infants, possibly because of maturational defect in albumin or presence of fetal albumin. 7 Metabolic products of stress or altered metabolism may block or interfere with sites. Indirect bilirubin (especially first 1 to 2 weeks) may alter albumin binding of drugs. Drugs displaced by bilirubin (such as phenytoin, ampicillin, penicillin, or phenobarbital) lead to higher levels of free drug, increasing clearance and the potential for toxicity. Other drugs (such as sulfonamides, salicylates, or chloral hydrate) or excess free fatty acids may displace bilirubin, increasing free bilirubin levels. 8 Hepatic uptake of many substances is decreased initially primarily because of decreased activity of ligandin, which is low for the first 5 to 10 days in term infants and may be longer in preterm infants. 8 Activity levels of many hepatic microsomal enzymes are reduced. 7 Activity increases after birth, so by a few weeks'/months' activity some reactions may exceed adult levels for enzymes that metabolize drugs such as theophylline, phenobarbital, and phenytoin. 7, 8 Examples of alterations in hepatic metabolism in the neonate, especially preterm infants, include the prolonged elimination of phenytoin and diazepam and the erratic and variable hydrolysis of chloramphenicol. 2 Newborns have a decreased ability to metabolize methylxanthines, but compensate by converting theophylline to caffeine, which is less toxic. The consequences of altered liver function are altered drug metabolism, extended half-life on drugs dependent on liver enzymes for metabolism, and an increased risk of drug intolerance. Hypoxia may further alter hepatic drug handling. Alterations in renal function include decreased renal blood flow and glomerular filtration rate, and altered tubular function. Renal function changes rapidly with birth, especially in the first 10 to 14 days. In preterm infants, the changes are related to both postconceptional and postbirth age, since infants do not develop a full compliment of nephrons until after 34 to 35 weeks gestation. Altered renal function in newborns results in delayed clearance of drugs and metabolites and longer half-lives of drugs excreted by glomerular filtration (such as gentamycin and digoxin) or by tubular secretion (such as penicillins). 2, 7 Because of alterations in renal function in the neonate, dosing intervals may be longer and there is a very narrow margin of safety with fluid and electrolyte therapy.
Pharmacologic management of the neonate must consider both postconceptional and postbirth changes in physiologic function. Both influence neonatal drug handling, dosage, dosing intervals, efficacy, choice of drugs, and monitoring. Handling of drugs can be variable even in infants of similar postconceptional and postbirth ages and can vary markedly in individual infants within a few days, especially in the first 2 to 3 weeks postbirth.
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